Cabot vs Chemours
Add, change or remove companies; up to four.
The short version
- Chemours is the larger business, with $5.8B of revenue in fiscal 2025 against $3.7B for Cabot, about 1.6 times as much.
- Chemours grew revenue faster (0.5%, against −7.0%).
- Cabot turned more of its sales into free cash flow (10.5% FCF margin, against 0.9%).
- Cabot earned a higher return on the capital invested in it (15.9%, against −0.2%).
| Latest fiscal year | CBT · FY25 | CC · FY25 |
|---|---|---|
| Size | ||
| Market cap | $3.9B | $1.9B |
| Revenue | $3.7B | $5.8B |
| Free cash flow | $391M | $51.0M |
| Net income | $331M | −$386M |
| Growth | ||
| Revenue growth | −7.0% | 0.5% |
| 5-year growth | 7.3% | 3.2% |
| Share count change | −2.7% | 0.0% |
| Profitability | ||
| Gross margin | 25.3% | 15.5% |
| Operating margin | 16.7% | — |
| Net margin | 8.9% | −6.7% |
| FCF margin | 10.5% | 0.9% |
| Return on capital | 15.9% | −0.2% |
| Return on equity | 22.3% | −94.0% |
| Balance sheet | ||
| Net debt | $878M | $3.5B |
| Net debt / EBITDA | 1.1x | 10.6x |
| Dividends and buybacks | $264M | $78.0M |
| Valuation & quality | ||
| P/E | 12.9x | — |
| Piotroski F-score | 6 | 4 |
Revenue
FY16
CBT $2.4B
CC $5.4B
FY17
CBT $2.7B
CC $6.2B
FY18
CBT $3.2B
CC $6.6B
FY19
CBT $3.3B
CC $5.5B
FY20
CBT $2.6B
CC $5.0B
FY21
CBT $3.4B
CC $6.3B
FY22
CBT $4.3B
CC $6.8B
FY23
CBT $3.9B
CC $6.1B
FY24
CBT $4.0B
CC $5.8B
FY25
CBT $3.7B
CC $5.8B
CBT
CC
Operating margin
FY16
CBT 10.2%
CC —
FY17
CBT 12.4%
CC —
FY18
CBT 4.4%
CC —
FY19
CBT 9.2%
CC —
FY20
CBT 0.8%
CC —
FY21
CBT 13.3%
CC —
FY22
CBT 9.0%
CC —
FY23
CBT 13.4%
CC —
FY24
CBT 15.4%
CC —
FY25
CBT 16.7%
CC —
CBT
CC
Free cash flow
FY16
CBT $280M
CC $256M
FY17
CBT $201M
CC $229M
FY18
CBT $69.0M
CC $642M
FY19
CBT $139M
CC $169M
FY20
CBT $177M
CC $540M
FY21
CBT $62.0M
CC $537M
FY22
CBT −$111M
CC $448M
FY23
CBT $351M
CC $186M
FY24
CBT $451M
CC −$993M
FY25
CBT $391M
CC $51.0M
CBT
CC
Return on capital
FY16
CBT 9.4%
CC 5.0%
FY17
CBT 13.8%
CC 29.5%
FY18
CBT 3.3%
CC 31.9%
FY19
CBT 10.7%
CC 1.7%
FY20
CBT 0.9%
CC 10.1%
FY21
CBT 16.4%
CC 21.6%
FY22
CBT 12.4%
CC 19.9%
FY23
CBT 22.2%
CC −2.4%
FY24
CBT 19.5%
CC 6.3%
FY25
CBT 15.9%
CC −0.2%
CBT
CC
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.